A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Key Inclusion criteria * Biopsy proven aggressive non-hodgkin's lymphoma * Follicular center lymphoma Grade 3. * Diffuse large B-cell lymphoma. * Mantle cell lymphoma. * Transformed lymphoma. * Relapsed or refractory to previous therapy for lymphoma * At least one prior combination chemotherapy regime * Measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter * Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2 * Willing to follow the pregnancy precautions Key Exclusion criteria * Any of the following laboratory abnormalities. * Absolute neutrophil count (ANC) \< 1,500 cells/mm\^3 (1.5\*10\^9/L). * Platelet count \< 60,000/mm\^3 (60\*10\^9/L). * Calculated creatinine clearance of \<50mL/min * Serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) or Serum glutamic pyruvic transaminase/Alanine transaminase (SGPT/ALT) 5.0 times upper limit of normal (ULN). * Serum total bilirubin \> 2.0 mg/dL (34 µmol/L)/conjugated bilirubin \>0.8mg/dL. * Subjects who are candidates for and willing to undergo an autologous stem cell transplant. * History of active Central Nervous System (CNS) lymphoma within the previous 6 months * History of other malignancies within the past year * Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C